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Abstract 
Innate lymphoid cells (ILCs) are a population of lymphocytes that act as the first line of immunologic 
defense at mucosal surfaces. The ILC family in the skin, lungs, and gastrointestinal tissues has been 
investigated, and there are reports of individual subsets of ILCs in the oral tissues. We sought to 
investigate the whole ILC population (group 1, 2, and 3 subsets) in the murine gingivae and the lymph 
nodes draining the oral cavity. We show that ILCs made up a greater proportion of the whole CD45+ 
lymphocyte population in the murine gingivae (0.356% ± 0.039%) as compared with the proportion of 
ILCs in the draining lymph nodes (0.158% ± 0.005%). Cytokine profiling of the ILC populations 
demonstrated different proportions of ILC subsets in the murine gingivae versus the regional lymph 
nodes. The majority of ILCs in the draining lymph nodes expressed IL-5, whereas there were equal 
proportions of IFN-γ- and IL-5 expressing ILCs in the oral mucosa. The percentage of IL-17+ ILCs was 
comparable between the murine gingivae and the oral draining lymph nodes. These data suggest an 
enrichment of ILCs in the murine gingivae, and these ILCs reflect a cytokine profile discrepant to that 
of the local draining lymph nodes. These studies indicate diversity and enrichment of ILCs at the oral 
mucosal surface. The function of ILCs in the oral cavity remains to be determined; here, we provide a 
premise of ILC populations that merits future consideration in investigations of mouse models and 
human tissuus. 
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Introduction 
The balance between the host immune response and the external environment is essential in 
maintaining a healthy state. Inappropriate barrier immune responses at the oral mucosa may drive the 
onset and progression of oral inflammatory diseases such as gingivitis and periodontitis (Lamont and 
Hajishengallis 2015). 
In humans, myriad mechanisms form a first line of innate immunity to microbial challenges at the oral 
mucosal barrier, including migrating and resident granulocytes/neutrophils, a network of 
antigen-presenting cells, and a small family of innate lymphoid cells (ILCs; Dutzan et al. 2016). ILCs 
constitute a recently identified family of lymphocytes that lack characteristic lineage markers. ILCs are 
found in secondary lymphoid tissues and at mucosal surfaces of the lung and gastrointestinal (GI) 
tract (Sonnenberg and Artis 2015). ILCs have emerged as important regulators in tissue homeostasis 
and mucosal barrier control of commensal and pathogenic microorganisms (Sonnenberg et al. 2012; 
Hepworth et al. 2015; Klose and Artis 2016). The ILC family encompasses 3 functional groups: group 
1, ILC1s and natural killer cells; group 2, ILC2s; and group 3, ILC3s (McKenzie et al. 2014). Human 
and mice ILC subsets have been defined by their cell surface markers and transcription factor 
expression; it is widely understood that all ILCs are lineage negative (Lin–) and express the interleukin 
7α (IL-7α) receptor (CD127), while “conventional” natural killer cells, although Lin–, do not express 
CD127 (Eberl et al. 2015)  
CD117 (c-KIT), the mast/stem cell growth factor receptor, and NKp46 (CD355), the natural 
cytotoxicity triggering receptor 1 (NCR1), have been identified as markers for phenotyping ILCs into 
subsets. ILCs are heterogeneous, and the expression of CD117 and NKp46 varies depending on 
anatomic location (Spits et al. 2013; Ealey and Koyasu 2017; Simoni and Newell 2017). 
The ILC subsets possess unique cytokine profiles that parallel those of T-helper cells: group 1 ILCs 
(ILC1) release interferon γ (IFN-γ); group 2 ILCs (ILC2) secrete group 2 cytokines, such as IL-4 and 
IL-5; and group 3 ILCs (ILC3) generate IL-17 and/or IL-22 (Spits et al. 2013). Group 1 ILCs promote 
immunity to intracellular bacteria and parasites (Klose et al. 2014; Klose and Artis 2016). ILC2s 
facilitate antihelminth and antiviral immunity (Chang et al. 2011; Moro et al. 2010; Neill et al. 2010) 
and are involved in orchestrating the immune response to allergens (Drake and Kita 2014; Halim et al. 
2014). ILC3s augment the removal of extracellular bacteria and fungi (Cella et al. 2009; Killig et al. 
2014; Van Maele et al. 2014). 
The importance of ILCs as the first line of defense at barrier sites has been highlighted in 
different murine models of mucosal infection. During infection with the gram-positive respiratory 
pathogen Streptococcus pneumoniae, lung-resident ILC3s produced elevated levels of IL-17 and 
IL-22—2 cytokines essential in mucosal defense (Van Maele et al. 2014). Similarly, IL-17 and 
IL-22-production by ILC3s was observed during gut infections with Citrobacter rodentium, a 
gram-negative enteric bacterium that causes experimental colitis (Sonnenberg et al. 2012; Rankin et 
al. 2016). Furthermore, loss of IL-5-producing lung-resident ILC2s in a murine model of influenza A 
acute viral infection resulted in exacerbated disease phenotype (Monticelli et al. 2011). In the Peyer’s 
patches of the gut, in vivo depletion of ILC1s and ILC3s interfered with the anatomic containment of 
commensal bacteria, indicating an essential role for ILCs in bacterial homeostasis in the gut 
(Hashiguchi et al. 2015). Other studies described an essential role for IFN-γ-producing ILC1s in 
Campylobacter jejuni–induced colitis (Muraoka et al. 2016). 
Over recent years, the ILC family has been the subject of extensive research of the skin, 
lungs, and GI tract, but the role of ILCs in the oral mucosa is not fully understood. To our knowledge, 
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ILCs (belonging largely to the ILC1 subset) have been identified in human gingival tissue (Dutzan et 
al. 2016), but a description of ILC populations in murine gingivae is restricted to the IL-17-producing 
ILC3 subset (Moutsopoulos et al. 2014; Pandiyan et al. 2014). Here, we sought to comprehensively 
characterize the ILC compartment within the murine gingivae and cervical oral draining lymph nodes 
(dLNs). 
Methods 
Animals 
Female BALB/c and C57BL/6 mice (both Envigo) were maintained in specific pathogen-free 
conditions with ad libitum access to food and water at the University of Glasgow. All animal work was 
approved by local research ethics committees and performed under license in accordance with UK 
Home Office regulations and conforms to the ARRIVE guidelines. 
Tissue Processing 
Preparation of gingival tissue single-cell suspensions followed a similar protocol as previously 
described (Mizraji et al. 2013). Single-cell suspensions were pooled from 4 or 5 mice per experiment 
for immediate phenotyping of ILCs or 9 to 11 mice per experiment for cytokine profiling of ILCs. 
Single-cell suspensions were obtained from 4 superficial cervical oral dLNs from each mouse 
by mechanically mashing the tissue through 40-μm cell strainers into sterile cRPMI (RPMI-1640 with 
10% fetal calf serum, 1% penicillin streptomycin, 1% l-glutamine; Gibco). 
Flow Cytometry 
For immediate phenotyping of ILCs, a 1/200 dilution of Fc block (anti-mouse CD16/32; eBioscience) 
in phosphate-buffered saline was added; then, cells were stained with fluorochrome-labeled cell 
surface antibodies against CD3, B220, CD11b, CD11c, Ly-6G (all Alexa Fluor 488; lineage 
“dumpgate”), CD127-phycoerythrin (PE), NKp46-allophycocyanin (APC), viability dye eFluor450 (all 
eBioscience), CD45–brilliant violet (BV510), and CD117-APC-Cy7 (Biolegend). For cytoplasmic 
intracellular cytokine staining of the ILCs, cells were stimulated in cRPMI media supplemented with 30 
ng/mL of phorbol myristate acetate, 500 ng/mL of ionomycin (both Sigma Aldrich), and GolgiPlug as 
specified by the intracellular cytokine staining protocol of BD Biosciences. Following stimulation, cells 
were stained with antibodies specific to CD3, B220, CD11b, CD11c, Ly-6G, and CD45 and with a 
viability dye, as described earlier, in addition to CD127-PE or CD127-APC (eBioscience). Cells were 
then fixed and permeabilized with the intracellular fixation and permeabilization buffer set 
(eBioscience) and stained with fluorochrome-labeled antibodies specific for IFN-γ and IL-17 (both 
PE-Cy7; eBioscience) or IL-5-PE (eBioscience). Positive and negative gates were applied with 
reference to “fluorescence minus one” or unstimulated controls. Cells were analyzed with a MACS 
Quant (Miltenyi Biotec) flow cytometer and the data analyzed with FlowJo (Tree Star Inc.). 
Statistical Analyses 
Normally distributed data were analyzed by 2-tailed Student’s t test to compare the means of 2 
samples or multiple-comparison 1-way analysis of variance to compare the means of >2 samples with 
GraphPad Prism 7. Values are presented as mean ± SEM. 
Results 
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Single-cell suspensions from the gingivae and oral dLNs were isolated and stained for CD3, B220, 
CD11b, CD11c, Ly-6G, CD45, CD127, CD117, and NKp46. Dead cells were excluded with a 
Live/Dead Viability dye ILCs were initially identified by positive expression of CD45, a marker present 
on all hematopoietic cells (including ILCs) and then further characterized per a lack of expression of 
common lineage markers (Lin–; CD3, B220, CD11b, CD11c, Ly-6G) in conjunction with expression of 
CD127 (IL-7 receptor α) as seen in Figure 1A (full gating strategy shown in Appendix Fig. 1). The 
proportion of total ILCs of the whole CD45+ lymphocyte population was compared between gingivae 
and dLNs. There was a significantly higher percentage of total ILCs in the gingivae as compared with 
the oral dLNs (Fig. 1B; 0.356% ± 0.039% total ILCs of the CD45+ lymphocyte population for gingivae 
vs. 0.158% ± 0.005% for oral dLNs, P < 0.001). 
 
Figure 1. 
Percentage of innate lymphoid cells (ILCs) from CD45+ lymphocytes in cervical draining lymph nodes 
(dLNs) and gingivae. Superficial cervical oral dLNs and gingivae were harvested from BALB/c mice 
and processed, with single-cell suspensions stained for antibodies prior to analysis by flow cytometry. 
(A) ILCs were identified as CD45+, lineage– (Lin–; CD3–, B220–, CD11b–, CD11c–, Ly-6G–), and 
CD127+ lymphocytes. For full gating strategy, see Appendix Figure 1. Flow cytometry plots are from a 
representative gingivae cell sample. (B) Percentage of ILCs from the whole CD45+ lymphocyte 
population in the oral dLNs (clear bars) versus gingivae (shaded bars). Data are presented as mean 
percentage ± SEM of CD45+ lymphocyte population, representing a 6 independent experiments (n = 
oral dLNs, 4 or 5 mice per group/experiment, gingivae pooled from a 4 or 5 mice per 
group/experiment). Statistical significance determined by 2-tailed unpaired t test (***P < 0.001). 
FSC-A, forward scatter area.  
CD45+, Lin–, CD127+ cells were further characterized by expression of CD117 (c-KIT; i.e., 
the mast/stem cell growth factor receptor) and NKp46 (CD355; i.e., NCR1) (Appendix Fig. 1; 
summarized in Fig. 2A). Identification of ILCs into possible “subsets” with CD117 and NKp46 is 
described in Appendix Table 1. There was no significant difference in the percentages of CD117–, 
NKp46– ILCs in the gingivae as compared with the oral dLNs (Appendix Fig. 2A; 0.182% ± 0.038% vs. 
0.128% ± 0.010%, P < 0.194). However, there was a significantly higher percentage of CD117+, 
NKp46– ILCs (Appendix Fig. 2B; 0.1346% ± 0.0187% vs. 0.0077% ± 0.0005%, P < 0.0001), CD117–
, NKp46+ ILCs (Appendix Fig. 2C; 0.0513% ± 0.0039% vs. 0.0169% ± 0.0019%, P < 0.0001), and 
CD117+, NKp46+ ILCs (Appendix Fig. 2D; 0.0208% ± 0.0036% vs. 0.0060% ± 0.0007%, P < 0.01) in 
the gingivae versus the oral dLNs. Collectively, these data suggest a proportional enrichment of ILCs 
at the gingival mucosal surface as compared with the oral dLNs. 
To determine the relationship between the CD117±, NKp46± ILC populations (identified with 
plots in Fig. 2A, full gating strategy in Appendix Fig. 1) in the gingivae and oral dLNs, the proportion of 
these ILCs from the whole ILC population (e.g., CD45+, Lin–, CD127+ lymphocytes) was also 
compared. The ILC subsets (e.g., CD117±, NKp46± ILCs) of the whole ILC population were more 
diverse in the gingivae than in the oral dLNs. The majority of ILCs in the gingivae and lymph nodes 
were CD117–, NKp46– ILCs (Fig. 2B; 45.57% ± 4.40% vs. 79.99% ± 0.95%, respectively, P < 
0.0001), while the percentage of CD117+, NKp46– ILCs was significantly higher in the gingivae than 
the oral dLNs (Fig. 2C; 35.19% ± 3.84% vs. 5.03% ± 0.69%, P < 0.0001). There was no statistically 
significant difference between the percentage of CD117–, NKp46+ ILCs in either tissue (Fig. 2D; 
13.81% ± 1.70% [gingivae] vs. 10.53% ± 0.59% [lymph node], P = 0.0978) nor CD117+, NKp46+ ILCs 
in the gingivae and oral dLNs (Fig. 2E; 5.43% ± 0.79% vs. 3.93% ± 0.59%, respectively, P = 0.1593). 
These data suggest that the majority of ILCs in the oral cavity are CD117– and NKp46– (Fig. 3F, G, 
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blue segment; ~45.57% in the gingivae and ~79.99% in the oral dLNs), although a significant 
proportion of ILCs in the gingivae is phenotypically CD117+ and NKp46– (Fig. 3G, red segment; 
~35.19%). 
Figure 2. 
Proportion of subsets of innate lymphoid cells (ILCs) from the CD45+, lineage– (Lin–), CD127+ 
population in murine cervical draining lymph nodes (dLNs) and gingivae. Superficial cervical oral 
dLNs and gingivae were harvested from BALB/c mice and single-cell suspensions analyzed by flow 
cytometry. (A) Four populations of ILCs (CD45+, Lin–, CD127+ lymphocytes) were identified with 
CD117 and NKp46. Flow cytometry plots are from a representative gingivae cell sample. The 
percentage of each ILC subset as a proportion of the ILC population, compared between the dLNs 
(clear bars) and gingivae (shaded bars): (B) CD117–, NKp46–; (C) CD117+, NKp46–; (D) CD117–, 
NKp46+; (E) CD117+, NKp46+. The diversity of the ILC populations: (F) dLNs and (G) gingivae. (B–
E) The mean percentage ± SEM of CD45+, Lin–, and CD127+ lymphocyte population, representing 6 
independent experiments (n = oral dLNs, 4 or 5 mice per group/experiment, gingivae pooled from 4 or 
5 mice per group/experiment). Statistical significance determined by 2-tailed unpaired t test (****P < 
0.0001). 
We next characterized the cytokine profiles of ILCs via intracellular cytokine staining (full 
gating strategy shown in Appendix Fig. 3). Figure 3A shows the final flow cytometry plots used for 
identification of IFN-γ-producing ILCs (group 1 ILCs), IL-5-producing ILCs (ILC2s), and 
IL-17-producing ILCs (ILC3s; summarized in Appendix Table 1). We also investigated cytokine 
expression in the total CD45+ population and compared this with the cytokine expression by the ILCs. 
The majority of the CD45+ lymphocytes in the oral dLNs expressed IFN-γ (Fig. 3B, blue segment; 
79.26% ± 4.45%), with a significantly lower proportion of IL-5-producing cells (Fig. 3B, red segment; 
11.45% ± 3.36%, P < 0.0001) and IL-17+ cells (Fig. 3B, green segment; 9.29% ± 1.41%, P < 0.0001). 
The cytokine profile of the total CD45+ lymphocytes in the gingivae was similar to that of the oral 
dLNs, with the majority of cells expressing IFN-γ (Fig. 3C, blue segment; 77.69% ± 1.50%). 
Compared with the IFN-γ producing cells, there were fewer IL-5+ cells (Fig. 3C, red segment; 3.65% ± 
0.40%, P < 0.0001) and more IL-17-producing cells (Fig. 3C, green segment; 18.66% ± 1.9%, P < 
0.0001). The ILC subsets in gingivae and dLNs showed a quite different distribution when compared 
with the CD45+ population. There was a significantly greater proportion of IL-5-producing ILCs (Fig. 
3D, red segment; 62.55% ± 1.48%) isolated from the oral dLNs than IFN-γ+ ILCs (Fig. 3D, blue 
segment; 19.36% ± 1.35%, P < 0.0001) or IL-17 producing ILCs (Fig. 3D, green segment; 18.09% ± 
2.26%, P < 0.0001), suggesting that the ILC2 subset was the most prominent ILC cell type in the dLN. 
There was an equal proportion of IFN-γ- and IL-17-producing ILCs in the dLNs (P = 0.9969). In the 
gingivae, there was an equal proportion of IFN-γ+ ILCs (Fig. 3E, blue segment; 42.27% ± 6.63%) and 
IL-5+ ILCs (Fig. 3E, red segment; 39.60% ± 4.12%) and a significantly lower proportion of 
IL-17-producing ILCs (Fig. 3E, green segment; 18.13% ± 2.50%, P < 0.001). Unlike the cytokine 
profile of the CD45+ lymphocytes, the proportion of IFN-γ+, IL-5+, and IL-17+ ILCs differed between 
the ILCs resident in the 2 oral tissues. The cytokine production of the total lymphocyte population (all 
CD45+) was similar in the gingivae and the dLN (Fig. 3F). However, there were marked differences in 
the cytokine expression of the ILC population in the gingivae versus the dLN. There was a significantly 
greater proportion of IFN-γ-producing ILCs in the gingivae than the oral dLNs (Fig. 3G, 42.27% ± 
6.63% vs. 19.36% ± 1.35%, respectively, P < 0.001). The population of IL-5+ ILCs was significantly 
reduced in the gingivae than the oral dLNs (Fig. 3G; 39.60% ± 4.12% vs 62.55% ± 1.48%, 
respectively, P < 0.001). The proportion of IL-17+ ILCs was comparable in gingivae and oral dLNs 
(Fig. 3G; 18.13% ± 2.50% vs. 18.09% ± 2.26%, respectively P = 0.9999). Appendix Table 2 presents 
a summary of the statistical significance between ILC subsets in the gingivae and oral dLNs. Taken 
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together, these data suggest that the gingivae-resident ILCs have a more diverse cytokine profile than 
the population of ILCs in the oral dLNs and that the cytokine profile of the ILCs is distinct to that of the 
total CD45+ population in both tissues. 
Figure 3. 
Comparison of the proportion of cytokine-producing innate lymphoid cells (ILCs) in the murine 
gingivae and oral dLNs. Superficial cervical oral draining lymph nodes (dLNs) and gingivae were 
harvested from C57BL/6 mice and processed to obtain single-cell suspensions; then, cells were 
stimulated with PMA/ionomycin and protein release inhibitors for 6 h prior to staining for innate 
lymphoid cell (ILC) markers and cytokines. (A) ILCs (CD45+, lineage– [Lin–], CD127+ lymphocytes) 
were divided into 3 subsets according to production of IFN-y (ILC1s), IL-5 (ILC2s), and IL-17 (ILC3s). 
Plots show gingival cells from a representative experiment. (B–E) Mean percentage of each 
cytokine-producing cell type from the cytokine-producing population in both oral tissues: CD45+ 
lymphocytes and ILCs in dLNs and gingivae. The mean proportion ± SEM of cytokine-producing 
(IFN-γ, IL-5, and IL-17) (F) CD45+ lymphocytes and (G) ILCs. Data represent 2 independent 
experiments (dLNs pooled from 4 or 5 mice per group/experiment) and gingivae (gingivae pooled 
from 9 to 11 mice per group/experiment). (F, G) Statistical significance determined by 
multiple-comparison 1-way analysis of variance (***P < 0.001, ****P < 0.0001). FSC-A, forward 
scatter area. 
 
Discussion 
We demonstrate here that the ILC compartment is enriched and more diverse and has a different 
cytokine profile at the gingival mucosal surface as compared with that of the oral dLNs. The majority of 
the ILCs in the oral dLNs and gingivae were CD117–, NKp46–, although there was a substantial 
population of CD117+, NKp46– ILCs at the mucosal surface. This cell surface phenotype suggested 
that oral-resident ILCs were mainly ILC1s. Upon further investigation with cytokine analysis, the ILCs 
in the oral dLNs largely produced IL-5, indicating that these ILCs were predominantly part of the type 
2 subset, with an equal distribution of IFN-γ- and IL-17-producing ILCs. In the gingivae, there was a 
relatively similar proportion of IFN-γ+ and IL-5+ ILCs. Such a discrepancy in cell surface marker and 
cytokine analysis in oral-resident ILCs may have arisen from 1) differences in staining methods for ex 
vivo versus in vitro stimulated cells—that is, the cytokine production was analyzed after a period of in 
vitro stimulation, whereas the cell surface phenotype was analyzed immediately ex vivo—and/or 2) 
the heterogenous nature and potentially plasticity of ILCs (Simoni and Newell 2017). Ideally, large 
numbers of purified ILCs would be obtained from oral tissues and studied over time with different 
stimulation conditions. Currently, there are no methods of growing these cells in vitro, and their 
isolation into “pure” populations for in vitro study is extremely challenging given the small numbers 
and proportions of cells in tissue. Nonetheless, we show that the cytokine profile of the ILCs differed 
from the whole CD45+ lymphocyte population in the oral dLNs and gingivae; IFN-γ was evidently the 
main cytokine produced by the CD45+ lymphocytes in both tissues. 
The ILC compartment is enriched at mucosal surfaces, such as the respiratory and GI tracts 
and the skin, as compared with regional draining lymph nodes (Sonnenberg and Artis 2015; Kim et al. 
2016) (percentage of ILCs of total CD45+ lymphocytes: 3.7% for lung, 2.5% for small intestine lamina 
propria, 1.8% for large intestine lamina propria, and 3.5% for skin vs. <0.2% for regional draining 
lymph nodes). However, there is no work describing an enrichment of ILCs at the oral mucosa as 
discussed here. As previously shown, ILC populations are more diverse at the mucosal surface of the 
lower GI tract (e.g., the lamina propria and intraepithelial compartment of the small and large 
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intestines) as compared with the draining mesenteric lymph nodes (Kim et al. 2016). The data 
presented here suggest that a similar phenomenon occurs in the oral mucosa, with an enrichment of 
ILCs and a more diverse ILC population in the gingivae as compared with the oral dLNs. It is 
postulated that the increased number of ILCs at mucosal surfaces reflects the importance of these 
cells as a first-line regulation of innate and adaptive immunity to commensal and harmful microbiota, 
specifically in the GI tract and lungs (Klose and Artis 2016). Immune tolerance in CD4+ T cells to 
commensal bacteria is essential in maintaining tissue homeostasis in the GI tract (Belkaid et al. 2013), 
a mechanism controlled in part by communication with gut-resident ILCs (Hepworth et al. 2013). It 
may be that a similar cross-talk between CD4+ T cells and ILCs is present in the oral cavity, given the 
vast population of microbes inhabiting the environment, including many commensal bacteria and 
fungi. Thus, the enrichment and enhanced diversity of the ILC populations in the gingivae may be 
expected given the constant microbial perturbations to the oral mucosal surface. 
It is generally accepted that the majority of ILCs are tissue-resident lymphocytes incapable of 
circulating around the body. Parabiotic studies with 2 conjoined adult mice that share 1 blood 
circulatory system demonstrated that ILCs in the small intestine lamina propria, salivary gland, lung, 
and adipose tissue are strictly tissue-resident cells and do not pass from one mouse to the other 
(Gaisteiger et al. 2015; O’Sullivan et al. 2016). Tissue-resident ILCs will expand locally under 
physiologic conditions in response to immunologic perturbations at mucosal surfaces and are only 
replenished in small numbers by hematogenous precursors and/or circulating mature ILCs 
(Gaisteiger et al. 2015). Nonetheless, other evidence suggests that a small population of ILCs is 
migratory and can traffic from the mucosal surface to secondary lymphoid organs through the 
expression of chemokine and homing receptors (Mackley et al. 2015; Kim et al. 2016). In the gingivae, 
other lymphocytes (e.g., T cells) can migrate to the secondary lymphoid tissue (Yamazaki et al. 2012). 
Currently, it is not known whether the gingivae-resident ILCs are capable of migrating to the oral dLNs 
and, if so, which subsets would undergo this migration and under what circumstances. Future work 
will ideally allude to such phenomena, which may also begin  
For the purposes of these investigations, we characterized ILCs into 3 “conventional” subsets 
in accordance with the production of cytokines: IFN-γ (ILC1s), IL-5 (ILC2s), and IL-17 (ILC3s). Dutzan 
et al. (2016) proposed that the most abundant ILC subtype in the human gingivae was strictly 
IFN-γ-producing ILC1s, with only a small percentage of IL-17+ ILC3s. They did not detect any ILC2 
populations in the human gingivae. Here we show that in the murine gingivae, there was a relatively 
equal proportion of ILC1s and ILC2s—based on their generation of IFN-γ and IL-5, respectively—and 
a further population of IL-17+ ILC3s. The variation in the gingivae-resident ILC subsets between mice 
and human may represent a true species-specific difference in ILC population distribution or an 
environmental consequence of variable microbial challenge between humans and specific pathogen–
free mice. This discrepancy may be evidence of further anomalies in the innate immune response in 
mice versus humans, with implications for the interpretation of animal model data (Zschaler et al. 
2014). Interestingly, previous studies that identified ILCs in the murine oral mucosa focused on the 
ILC3 population, with no work, to our knowledge, describing the ILC1 or ILC2 subsets within the 
tissue. Gingivae-resident ILC3s were identified as a source of IL-17 in an experimental model of 
leukocyte adhesion deficiency type I periodontitis (Moutsopolous et al. 2014), and small populations 
of ILC3s were found in oral mucosal lymphocytes isolated from the tongue, gingival, and palatal 
tissues (Pandiyan et al. 2014). To the best of our knowledge, this is the first appraisal of the whole ILC 
compartment within the murine gingival tissue, including the identification of ILC1s and ILC2s. 
The identification of IFN-γ-, IL-5-, and IL-17-producing ILCs in the gingival tissue may further 
complicate regulation of homeostasis and pathways involved in inflammation and infection at the oral 
mucosa. Nonetheless, the presence of such cells in the oral mucosa suggests that they may play a 
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role in oral health and diseases. Future work may merit the consideration of comparing ILC 
populations within other oral mucosal surfaces, such as the tonsils, tongue, and/or palatal tissues, to 
further aid future investigations in oral immunology. Ultimately, understanding the function of the 
complex network of different lymphocytes resident in the oral cavity will aid future work in developing 
novel therapeutics to target the myriad of oral diseases associated with microbial dysbiosis, infection, 
or inflammation. 
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